Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

BACKGROUND: Oncogenic K-Ras signaling highly relies on the canonical Ras/MEK/ERK pathway to contribute to pancreatic cancer progression. However, numerous efforts of MEK inhibitors have failed to provide an optimal antitumor effect for pancreatic cancer in practice. The aim of the present work was t...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Epigenetics
Main Authors: Chao, Min-Wu, Chang, Li-Hsun, Tu, Huang-Ju, Chang, Chao-Di, Lai, Mei-Jung, Chen, Yi-Ying, Liou, Jing-Ping, Teng, Che-Ming, Pan, Shiow-Lin
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2019
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6540419/
https://ncbi.nlm.nih.gov/pubmed/31142371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-019-0681-6
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares